These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1826)

  • 41. Nifedipine in neuroleptic-refractory schizophrenia.
    Kramer MS; DeMaria P; Morrow R; DiJohnson C; Sheves P
    J Clin Psychopharmacol; 1987 Jun; 7(3):195-6. PubMed ID: 2885346
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
    Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
    Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New antipsychotic medications: do research results relate to clinical practice?
    MacEwan GW
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S75-9. PubMed ID: 7504572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myth and reality of pragmatic trials.
    Mohr P; Bitter I; Constant E; Jakovljević M; Jarema M; Pecenak J; Seifritz E; Svestka J; Sartorius N
    Psychiatr Danub; 2010 Mar; 22(1):2-3. PubMed ID: 20305584
    [No Abstract]   [Full Text] [Related]  

  • 45. Piperacetazine in the treatment of mixed neurotics.
    Lapierre YD; Lee M
    Curr Ther Res Clin Exp; 1976 Jan; 19(1):105-9. PubMed ID: 1209
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical evaluation of centbutindole as an anti-psychotic agent.
    Doongaji DR; Sheth AS; Paul T; Parikh RM; Vahora SA; Apte JS; Desai NK; Upadhaya AK; Satoskar RS
    Indian J Med Res; 1983 Jul; 78():126-33. PubMed ID: 6139336
    [No Abstract]   [Full Text] [Related]  

  • 47. Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia.
    Buckley PF; Miller BJ; Pillai A; Kirkpatrick B
    Schizophr Res; 2014 Sep; 158(1-3):268-9. PubMed ID: 25052781
    [No Abstract]   [Full Text] [Related]  

  • 48. The influence of group therapy on schizophrenia.
    Malm U
    Acta Psychiatr Scand Suppl; 1982; 297():1-65. PubMed ID: 6126069
    [No Abstract]   [Full Text] [Related]  

  • 49. Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia.
    Perenyi A; Goswani U; Bela A; Freoska E; Arato M; Hegedus I
    Schizophr Res; 1988; 1(4):307-8. PubMed ID: 2908704
    [No Abstract]   [Full Text] [Related]  

  • 50. CT scans and neuropsychological tests as predictors of clinical response in schizophrenics.
    Smith RC; Largen J; Calderon M; Schoolar J; Shvartsburd A; Ravichandran GK
    Psychopharmacol Bull; 1983; 19(3):505-9. PubMed ID: 6138798
    [No Abstract]   [Full Text] [Related]  

  • 51. Antipsychotic effects of ceruletide in chronic schizophrenia. An appraisal of the long-term, intermittent medication of ceruletide in chronic schizophrenia.
    Moroji T; Itoh K; Itoh K
    Ann N Y Acad Sci; 1985; 448():518-34. PubMed ID: 3927809
    [No Abstract]   [Full Text] [Related]  

  • 52. Continuation rate for asenapine and brexpiprazole treatment in elderly patients with schizophrenia.
    Suzuki H; Hibino H; Inoue Y; Takaya A; Mikami K; Yamamoto K; Matsumoto H
    Psychogeriatrics; 2021 Nov; 21(6):950-951. PubMed ID: 34486199
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical Improvement in a Treatment-Resistant Patient With Schizophrenia Treated With Deep Brain Stimulation.
    Corripio I; Sarró S; McKenna PJ; Molet J; Álvarez E; Pomarol-Clotet E; Portella MJ
    Biol Psychiatry; 2016 Oct; 80(8):e69-70. PubMed ID: 27113497
    [No Abstract]   [Full Text] [Related]  

  • 54. A note on the drug-induced arterialization of venous blood in schizophrenics: possible microcirculation disturbances.
    Takei M
    Biol Psychiatry; 1989 Jan; 25(1):110-4. PubMed ID: 2563230
    [No Abstract]   [Full Text] [Related]  

  • 55. New antipsychotic drugs: special issues and indications. Symposium proceedings. Marco Island, Florida, USA. 20-21 February 1998.
    Schizophr Res; 1999 Mar; 35 Suppl():S1-109. PubMed ID: 10190220
    [No Abstract]   [Full Text] [Related]  

  • 56. A new antidepressant butriptyline: plasma levels and clinical response.
    Burrows GD; Norman TR; Maguire KP; Rubinstein G; Scoggins BA; Davies B
    Med J Aust; 1977 Oct; 2(18):604-6. PubMed ID: 579645
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of butaclamol in serum by fluorescence induction.
    Hasegawa J; Hurwitz A; Krol G; Davies R
    J Pharm Sci; 1976 Apr; 65(4):508-11. PubMed ID: 1271247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods.
    Imaz F; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of butaclamol in chronic schizophrenic patients.
    Clark ML; Paredes A; Costiloe JP; Wood F
    J Clin Pharmacol; 1977; 17(8-9):529-36. PubMed ID: 19510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.